Michael Lee Brooks - 02 Nov 2021 Form 3 Insider Report for Syneos Health, Inc.

Role
Chief Development Officer, Clinical Solutions
Signature
/s/ Sara Epstein, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
02 Nov 2021
Net transactions value
$0
Form type
3
Filing time
05 Nov 2021, 17:05:32 UTC
Next filing
20 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SYNH Class A Common Stock 32,999 02 Nov 2021 Direct F1
holding SYNH Class A Common Stock 9,527 02 Nov 2021 By spouse F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes (i) 2,344 shares of restricted stock units ("RSUs") that vest on January 15, 2022; (ii) 8,655 RSUs that vest on February 16, 2022; (iii) 2,344 RSUs that vest on January 15, 2023; (iv) 8,656 RSUs that vest on February 16, 2023; (v) 2,344 RSUs that vest on January 15, 2024; and (vi) 8,656 RSUs that vest on February 16, 2024, all subject to continued employment.
F2 Includes (i) 1,348 RSUs that vest on December 16, 2021; (ii) 2,742 RSUs that vest on January 15, 2022; (iii) 1,347 RSUs that vest on December 16, 2022; (iv) 2,742 RSUs that vest on January 15, 2023; and (v) 1,348 RSUs that vest on January 15, 2024, all subject to continued employment.

Remarks:

Chief Development Officer, Clinical Solutions